ArticleJournal of family medicine and primary care2025
Lichenoid dysplasia treated by apremilast - report of two cases and review of literature.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lichenoid dysplasia (LD) is a distinct clinicopathologic condition characterized by bilateral or unilateral oral lesions with a lichenoid pattern and atypical cells, giving it a higher risk for malignant transformation. Unlike oral lichen planus (OLP) or oral lichenoid lesions (OLL), LD lacks basal cell degeneration and shows an immune response to dysplastic cells rather than keratinocytes. This case series presents two female patients with LD, treated with Apremilast, a PDE4 inhibitor. Both patients experienced significant improvement after a 12-week treatment, as assessed by physician global assessment (PGA), subject global assessment (SGA), and target area lesion symptom score (TALSS). Apremilast reduced inflammation and promoted healing, without notable side effects aside from mild gastric irritation. This is the first known use of Apremilast in LD management, showing promising results and reinforcing LD as a distinct, non-tobacco-related entity with a potential immune response link. Further studies are needed to explore its long-term efficacy and transformation risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.